Interestingly, PEITC showed similar efficacy against CLL cell without 17p-deletion (Supplementary Figure S2), suggesting that this compound is equally effective in CLL cells regardless of the p53 status. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.